



Divi's Laboratories Limited

Date. 27th January 2018

To
The Secretary
National Stock Exchange of India Limited
Exchange Plaza,
Bandra-Kurla Complex, Bandra (East)
MUMBAI – 400 051

To
The Secretary
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street
MUMBAI – 400 001

Stock Code: DIVISLAB

Stock Code: 532488

Dear Sir/ Madam,

**Sub: Un-audited financial results for the quarter and nine months ended
31st December 2017 and limited review report –reg**
**Ref: Regulation 33 of the SEBI (Listing Obligations and Disclosure
Requirements), Regulations, 2015**

Further to our letter dated 18th January, 2018, we would like to inform that the Board of Directors of the Company at its meeting held on Saturday, 27th January 2018 has approved Un-audited Financial Results for the quarter and nine months ended 31st December, 2017.

In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we are enclosing herewith the following:

1. Un-audited Standalone Financial Results for the quarter and nine months ended 31st December, 2017.
2. Limited Review Report on the Standalone Financial Results
3. Press Release on the Financial Results of the Company

The Board meeting commenced at 15:30 Hrs and concluded at 17:30 Hrs

This is for your information and records.

Thanking You,

Yours faithfully,
For Divi's Laboratories Limited


P V Lakshmi Rajani
Company Secretary



“An ISO-9001, ISO-14001 and OHSAS-18001 Triple certified company”

Regd. Off. : Divi Towers, 1-72/23(P)/DIVIS/303, Cyber Hills, Gachibowli, Hyderabad - 500 032, Telangana, INDIA.

Tel : 91-40-2378 6300, **Fax :** 91-40-2378 6460, **CIN :** L24110TG1990PLC011854

E-mail : mail@divislaboratories.com, **Website :** www.divislaboratories.com

DIVI'S LABORATORIES LIMITED

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2017

(₹. in Lakhs)

	Particulars	Quarter ended			Nine Months ended		Year ended
		31.12.2017	30.09.2017	31.12.2016	31.12.2017	31.12.2016	31.03.2017
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Revenue from operations	103788	89020	97648	274928	299910	406577
2	Other Income	1701	3359	2171	6431	5505	7598
3	Total Revenue from Operations (1+2)	105489	92379	99819	281359	305415	414175
4	Expenses						
	a) Cost of materials consumed	40853	31352	34546	104357	112699	156319
	b) Purchases of stock-in-trade	0	0	0	0	0	0
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(15)	4378	516	5370	(644)	(2161)
	d) Employee benefits expense	11498	10482	10340	32050	38423	49031
	e) Depreciation and amortization expense	3739	3393	3095	10363	9182	12326
	f) Finance Costs	26	75	44	150	121	225
	g) Other Expenses	18838	15088	14490	46738	41856	59612
	Total expenses	74939	64768	63031	199028	201637	275352
5	Profit before exceptional Items and tax (3-4)	30550	27611	36788	82331	103778	138823
6	Exceptional items	0	0	0	0	0	0
7	Profit before Tax (5-6)	30550	27611	36788	82331	103778	138823
8	Tax Expense						
	a) Current Tax	6081	5544	7517	16452	23771	28523
	b) Deferred Tax	2003	1389	2439	5081	609	4973
	Total Tax Expense	8084	6933	9956	21533	24380	33496
9	Net Profit for the period (7-8)	22466	20678	26832	60798	79398	105327
10	Other Comprehensive Income: Items that will not be reclassified to Profit or Loss: - Remeasurement of post-employment benefit obligation (net of tax)	(37)	(38)	(30)	(111)	(160)	(140)
11	Total comprehensive Income for the period (9+10)	22429	20640	26802	60687	79238	105187
12	Paid-up Equity Share Capital (Face Value: ₹. 2 per share)	5309	5309	5309	5309	5309	5309
13	Other Equity						535582
14	Earnings per Share (of ₹. 2/- each) (not annualized)						
	a) Basic	8.46	7.79	10.11	22.90	29.91	39.68
	b) Diluted	8.46	7.79	10.11	22.90	29.91	39.68



Handwritten signature in green ink.



NOTES:

1. The above results, as reviewed by the Audit Committee, were considered and approved by the Board of Directors at its meeting held on 27th January, 2018.
2. Results for the quarter ended 31st December 2017 were subjected to 'limited review' by the Auditors and their report contains no qualification.
3. The Company is engaged in the manufacture of Active Pharmaceutical Ingredients and intermediates and the same constitutes a single reportable business segment as per Ind AS 108.
4. These financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under section 133 of the Companies Act, 2013 read with the relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
5. As per Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company has opted to publish quarterly unaudited standalone results and to publish consolidated results at the year end.
6. The company's Unit-II at Visakhapatnam was inspected by the US-FDA from 11th September 2017 to 19th September 2017. US-FDA has issued Establishment Inspection Report (EIR) for the same.
7. Post implementation of Goods and Service Tax (GST) effective from 1st July, 2017, revenue is reported net of GST as per Ind AS 18. Revenue, however, is reported inclusive of excise duty for the current and previous periods. Had the previously reported revenue been shown net of excise duty, comparative revenue of the company would have been as under:

	Quarter ended			Nine Months ended		Year ended
	31.12.2017	30.09.2017	31.12.2016	31.12.2017	31.12.2016	31.03.2017
Revenue from operations (net of excise duty)	103788	88752	96305	273803	296531	402386

8. Details of forex gain/(loss) are given below:

	Quarter ended			Nine Months ended		Year ended
	31.12.2017	30.09.2017	31.12.2016	31.12.2017	31.12.2016	31.03.2017
Forex gain/(loss)	(1597)	1059	65	163	(1006)	(3910)

Forex gain has been included in Other Income and loss has been included in Other Expenses.

9. Figures for the previous periods/year have been regrouped/reclassified wherever necessary.

Place: Hyderabad
Date: 27th January, 2018



for Divi's Laboratories Limited

Murali K. Divi
Dr. Murali K. Divi
Chairman & Managing Director



Price Waterhouse Chartered Accountants LLP

The Board of Directors
Divi's Laboratories Limited
Divi Towers, 1-72/23(P)/DIVIS/303,
Cyber Hills, Gachibowli,
Hyderabad- 500 032

1. We have reviewed the unaudited financial results of Divi's Laboratories Limited (the "Company") for the quarter ended December 31, 2017 which are included in the accompanying Statement of Standalone Unaudited financial results for the quarter and nine months ended December 31, 2017 (the "Statement"). The Statement has been prepared by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "Listing Regulations, 2015"), which has been initialled by us for identification purposes. The Statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement.
3. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with the applicable Accounting Standards prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies, and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. (a) The financial results of the Company for the quarter and nine months ended December 31, 2016 prepared in accordance with Companies (Indian Accounting Standards) Rules, 2015 were reviewed by another firm of chartered accountants who issued their unmodified conclusion, vide their report dated February 4, 2017.

(b) The financial statements of the Company for the year ended March 31, 2017 was audited by another firm of Chartered Accountants, who issued an unmodified opinion vide their report dated May 26, 2017.

Our conclusion is not qualified in respect of these matters.

For Price Waterhouse Chartered Accountants LLP
Firm Registration Number: FRN 012754N/N500016



Sunit Kumar Basu
Partner
Membership Number: 55000

Place: Hyderabad
Date: January 27, 2018

Price Waterhouse Chartered Accountants LLP, Plot No. 77/A, 8-2-624/A/1, 3rd Floor, Road No. 10, Banjara Hills
Hyderabad - 500 034
T: +91 (40) 4424 6000, F: +91 (40) 4424 6300

Registered office and Head office: Sucheta Bhawan, 11A Vishnu Digambar Marg, New Delhi 110 002

Price Waterhouse (a Partnership Firm) converted into Price Waterhouse Chartered Accountants LLP (a Limited Liability Partnership with LLP identity no: LLPIN AAC-5001) with effect from July 25, 2014. Post its conversion to Price Waterhouse Chartered Accountants LLP, its ICAI registration number is 012754N/N500016 (ICAI registration number before conversion was 012754N)

DIVI'S LABORATORIES LIMITED

CIN No.L24110TG1990PLC011854

1-72/23(P)/DIVIS/303, Cyber Hills, Gachibowli

Hyderabad – 500 032 Telangana, India

Phone: 91-40-23786300 email: kishore@divislabs.com

PRESS RELEASE dated 27th January, 2018

Divi's Labs earns PAT of Rs.225 crores in Q3/FY18

Quarter ended 31st December, 2017

Divi's Laboratories has earned a Profit after Tax (PAT) of Rs.225 crores on a total income of Rs.1055 crores, on a stand-alone basis, for the quarter ended 31st December, 2017. For the corresponding quarter of the last year, the company earned a PAT of Rs. 268 crores on a total income of Rs. 998 crores.

During the quarter, there was a forex loss of Rs.16 crores as against a forex gain of Rs. 0.65 crores during the corresponding quarter last year.

9-months ended 31st December, 2017

For the 9-month period ended 31st December, 2017, the company earned a total income of Rs. 2814 crores as compared to Rs. 3054 crores during the corresponding 9-month period of last year. PBT for the current 9-month period came to Rs. 823 crores as against a PBT of Rs. 1038 crores for the previous period. PAT for the current 9-months is Rs. 608 crores as against Rs. 794 crores.

Revenue in the first half of the current year was impacted due to the Import Alert issued by US-FDA, which has since been resolved.

Update on US-FDA inspection

The company's Unit-II at Visakhapatnam was inspected by the US-FDA from 11th September 2017 to 19th September 2017. US-FDA has issued Establishment Inspection Report (EIR) for the same.

